We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Tissue Regenix Group plc (TRX) ORD GBP0.001

Sell:61.00p Buy:62.00p 0 Change: No change
Market closed Prices as at close on 17 May 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:61.00p
Buy:62.00p
Change: No change
Market closed Prices as at close on 17 May 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:61.00p
Buy:62.00p
Change: No change
Market closed Prices as at close on 17 May 2024 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Tissue Regenix Group plc is a medical device company in regenerative medicine. The principal activity of the Company is the exploitation of platform technologies in the field of bone graft substitutes and soft tissue. It is focused on the development of regenerative products utilizing its two platform technologies, dCELL, addressing soft tissue needs, and BioRinse, providing sterile bone allografts. Its divisions include dCELL, BioRinse and GBM-V. The Company's patented decellularization technology (dCELL) removes DNA and other cellular material from animal and human soft tissue, leaving an acellular tissue scaffold not rejected by the patient's body that can be used to repair diseased or damaged body structures. Its proprietary BioRinse technology platform is primarily utilized to provide sterile tissue prepared in a manner to minimize the negative effects of processing. GBM-V produces tissue preparations for ophthalmology, primarily cornea, using conventional, classical methods.

Contact details

Address:
Unit 3
Phoenix Court, Lotherton Way, Garforth
LEEDS
LS25 2GY
United Kingdom
Telephone:
+44 (01904) 567609
Website:
https://www.tissueregenix.com/

Important dates

Future events
There are no future events available.
Past events
AGM 25 April 2024 25/04/24
Final results 19 March 2024 19/03/24
Trading Announcement 25 January 2024 25/01/24
Interim results 05 September 2023 05/09/23

General stock information

EPIC:
TRX
ISIN:
GB00BNTXR104
Market cap:
£43.40 million
Shares in issue:
70.57 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
n/a

Key personnel

  • Daniel Lee
    Chief Executive Officer, Executive Director
  • David Cocke
    Chief Financial Officer, Executive Director
  • Tina Trimble
    Senior Vice President of Donor Services, US
  • Patti Gary
    Vice President - Clinical Affairs
  • Lance Johnson
    Vice President of Quality and Regulatory, US
  • Gerald Sharpe
    Vice President - Strategic Partnerships
  • Christine Rowley
    Technical and Operations Director, UK
  • Kirsten Lund
    EMEA Business Director, Company Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.